Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moon_boy, you are full of crap. None of that is true. I'm a better speller than Red. LOL
I have no idea what post you are referring to with the edits you claim, but Red and I are separate investors and posters. If you want to join the JP clown posse with baseless claims, I'll simply add you to my ignore list as I've done with JP. Life is much better without JP's rhetoric.
And by the way, I respond to some of my own posts all the time... as when continuing a thread of information, or when updating weekly share count. This is nothing new. Red and others have done the same.
Novavax Stock May Soar 379% — The Motley Fool
https://www.fool.com/investing/2024/01/23/novavax-may-soar-379-wall-street-says/
Todos Share Update - 1/19/24
No shares issued since update on 12/8/23.
https://www.otcmarkets.com/stock/TOMDF/security
Link to U.S. Senate Committee Addressing Long Covid (currently in progress, includes video link)
https://www.help.senate.gov/hearings/addressing-long-covid-advancing-research-and-improving-patient-care
Todos Share Update - 1/12/24
No shares issued since update on 12/8/23.
https://www.otcmarkets.com/stock/TOMDF/security
Full transcript of Novavax at 42nd J.P. Morgan Healthcare Conference available at Seeking Alpha.
https://seekingalpha.com/article/4661979-novavax-inc-nvax-ceo-john-jacobs-presents-jpmorgan-42nd-annual-healthcare-conference
Novavax: Creating tomorrow’s vaccines today
pharmaphorum
January 10, 2024
https://pharmaphorum.com/rd/novavax-creating-tomorrows-vaccines-today
Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria, Novavax focuses solely on developing vaccines against some of the world’s most serious infectious threats. What sets it apart, though, is that its vaccines are protein-based.
Founded in 1987 in the US, Gale Smith – VP of vaccine development at Novavax – invented the technique of using insect cells for producing recombinant protein vaccines. A further milestone came in 1998 in Uppsala, with the development of adjuvants for veterinary use and for humans after that. By 2013, European Novavax AB was acquired by the US Novavax Inc, combining the two techniques of recombinant proteins and S-based adjuvants, Magnus Savenhed, managing director of Novavax AB, told journalists.
Creating immunological memory without causing disease
Before a tour of the facility, Dirk Poelaert, MD and senior director of medical affairs in Europe for Novavax, who has worked in vaccines for 20 years or so, explained that protein-based vaccines work, very simply, by protecting humans by triggering the immune system to produce antibodies against a specific pathogen, making a person sick and mimicking nature by providing an antigen. “In short, vaccines create immunological memory without causing disease,” he said.
Nonetheless, recombinant protein vaccines often need an adjuvant, or a substance that increases or modulates the immune response to a vaccine. This is why the Novavax vaccine platform comprises a recombinant protein particle plus Matrix-M adjuvant, which is manufactured in Uppsala itself.
Poelaert described how a recombinant protein particle has a native 3-dimensional conformation, with truncated S. frugiperda glycans and a particulate structure that facilitates antigen presentation and processing. Meanwhile, the Matrix-M adjuvant induces robust neutralising antibodies and induces polyfunctional CD4+TH1 lymphocytes (T helper cells). Formulation is in a nanoparticle with the recombinant protein particle.
Protein-based vaccines and recombinant expression systems
What might not be realised is that protein-based vaccines have existed for many decades for the prophylaxis of bacterial and viral diseases. They are indicated across the spectrum of infants, children, and adults, and have a favourable safety profile with well-known benefits. Nevertheless, originally the proteins used in vaccines were purified exclusively from cultures of an infectious agent, while today, specific immunogenic proteins can be generated through recombinant expression systems, said Poelaert.
Novavax takes the RNA sequence that codes and then incorporates into a baculovirus that can only infect insects, not humans. It uses the Sf9 cell, an ovary cell of an army moth, and the baculovirus enters the insect cell, including its nucleus, wherein it releases its genetic material. The machinery of this cell will produce the original protein had in mind, which then rises to the surface of the cell, where it is harvested and put into contact with the core, the polysorbate 80, the emulsifiers, and go towards a full vaccine.
Global public health: The malaria case
In terms of the global context, also in attendance was Dr Ole Olesen, PhD, executive director of the European Vaccine Initiative (EVI). EVI is an independent, non-profit research organisation that supports the development of safe and effective vaccines for global health – including affordability. It supports vaccine R&D through pre-clinical and clinical development, having helped with over 40 vaccine formulations. Dr Olesen noted how infectious diseases are often forgotten in the Western world.
“However, in the poorer parts of the world, infectious diseases are still a huge problem,” he reminded journalists. “More than 10 million people each year die from such. If one looks specifically at the malaria example, there are almost 250 million cases per year […] As a global community, this needs to be addressed.” Indeed, in 2022, there were 608,000 deaths from malaria across 85 countries worldwide.
As of December 2023, though, Novavax’s R21/Matrix-M malaria vaccine received pre-qualification from the World Health Organization (WHO), to prevent malarial disease in children caused by the P. falciparum parasite in endemic areas, allowing United Nations (UN) agencies to procure the vaccine in eligible countries and enable rollout of the vaccine.
The power of partnerships (and adjuvants)
Developed by the University of Oxford and the Serum Institute of India using Novavax’ saponin-based Matrix-M adjuvant – which helps stimulate immune responses to the vaccine – the R21/Matrix-M malaria vaccine has gained authorisation for use in children in Burkina Faso, Ghana, and Nigeria. Meanwhile, R21/Matrix-M is one of several ongoing collaborations involving Novavax’s adjuvant technology, with additional research in malaria and other infectious diseases in both humans and animals.
“In an ideal world, the disease burden should match the amount of research investment going into solving them,” he continued. “Malaria has, though, an enormous discrepancy between the disease burden and the amount of global investment. It costs over $500 million to develop a new vaccine, though; it is expensive, and this is a conservative figure. Some other projections are four or five times that amount. Clearly, it’s an expensive business. Additionally, there is a complexity to the disease itself […], and malaria has taken almost 150 years to get to the point now where there is a potential vaccine.”
“The immune system is like a sleeping dog,” Dr Olesen said. “Non-vaccinated, [it] remains asleep; immunised with active ingredient only, it remains in semi-dormancy. It is only when immunised with an active ingredient adjuvant that the dog is alive and kicking (and barking and biting, as one’s immune system should in the face of the infection). Companies like Novavax, with unique technologies like the Matrix-M adjuvant (the difference between a vaccine that works and doesn’t) need to engage in solving global health problems, a critical mass coming together, [and] the R21 malaria vaccine is an example of this, indeed.”
The pandemic period
During the pandemic, Novavax was operating under a joint contract with the EU Commission, delivering the vaccine through that (which came to an end at the close of 2023) to different governments around the world. Now, the company has initiated a transition into a “new and normal commercial situation in Europe,” Jorgen Persson, VP of market access and customer engagement, told journalists.
In different countries, governments are still considering their management of the vaccine post-pandemic, and so Novavax is in discussions with those governments. There is, Persson said, a dialogue from the perspective of delivering an updated vaccine that covers the needs of the space as it is now. The vaccine is approved in over 40 countries and recommended by the WHO. Well-positioned with proven technology, pipeline assets, commercial execution, and a focus on corporate development, Novavax’s platform seems to stand it in good stead for its desired future.
The value of vaccines
Previously, pharmaphorum had spoken with Alvar Paz, general manager for Europe at Novavax, and Silvia Taylor, executive vice president and chief corporate affairs and advocacy officer for Novavax, at the Economist Impact Future of Health Europe Summit in London. Taylor later partook in a fireside chat at the conference with Michael Guterbock on the value and power of vaccines.
Taylor joined Novavax in June 2020, right as the pandemic was hitting. In the time since, she’s helped to build the company from a very small, development-stage company to a global commercial organisation with authorisations around the world and commercial operations and manufacturing in Europe. Paz, meanwhile, joined Novavax two years later, in June 2022.
When it comes to public health, education is key, insisted Taylor: the availability, the choice, the options of vaccines. It's about trust. And Novavax hopes to be among the first companies to commercialise a combination vaccine (COVID and influenza).
“That's almost the holy grail, right?” she said. “If you think about it, it's two seasonal vaccines given in one jab. I think the convenience and the adherence to vaccination will greatly improve when you do combination products like this, but that is a few years away. We're still in phase two, and so I think we've got a couple of years more of our clinical development before we go to that.”
“I think the uniqueness of what Novavax is bringing to market is that we're the only protein-based option,” she continued. “It has advantages in terms of not needing to be frozen, it's refrigerator stable. I think, speaking to demand, you've got the consumer demand, you've also got the healthcare providers who have to administer. It's a really attractive profile.”
Remembering that COVID isn’t ‘done’
In October 2023, Novavax was given the go-ahead by regulators in the US for an updated version of its COVID-19 vaccine, which targets the XBB.1.5 variant of the coronavirus.
“COVID isn't done with us. It continues [and] it continues to change,” explained Taylor. “It continues to be something that we see a need for. In fact, in markets like the US, the recommendations are even broader than what we see in Europe in terms of giving accessibility to everybody in the market to get vaccinated as they choose. We think that's a great model. It's not the way it is here in Europe.”
“When you're talking about infectious diseases, you're not just vaccinating yourself for yourself, you're doing it for your community, you're doing it for your country,” she added. “You literally see things spreading. What we say about, "Nobody is safe until everybody is safe," is very, very much true.”
“We should be grateful to the mRNA vaccine, which is a pandemic vaccine, but ours is the endemic vaccine,” Paz noted. “A protein-based vaccine has proven the features that much better fit an endemic situation, [including] supply stability, temperature stability, even the product features themselves: efficacy, longer duration and durability, and safety profile.”
The press conference in Sweden might have been missing the Scandinavian summer light, but it appears that the light of vaccine-protective hope is burning brightly at Novavax, from COVID to malaria, and beyond.
Virtual webcast link to 42nd Annual J.P. Morgan Healthcare Conference NVAX. Definitely worth a listen. Bright future for Novavax with clear focus on cutting unnecessary expenses and growing business.
https://ir.novavax.com/events?year=2024&month=1#nav
Click on Virtual webcast link, which redirects you to J.P. Morgan website. Enter info to access webcast. Recommend opt-out of info sharing, or enter made-up data (for those who prefer not to have to provide personal info) as no email confirmation is required to access the webcast.
Novavax: Implied upside of 600% - The Motley Fool
3 Turnaround Stocks With 151% to 600% Upside in 2024, According to Select Wall Street Analysts
Sean Williams, The Motley Fool
Tue, January 9, 2024, 5:21 AM EST
https://finance.yahoo.com/news/3-turnaround-stocks-151-600-102100466.html
Novavax: Implied upside of 600%
The comeback story of the year, at least based on the price target of one Wall Street analyst, may be biotech stock Novavax (NASDAQ: NVAX). Despite tumbling more than 98% from its all-time high, H.C. Wainwright analyst Vernon Bernardino foresees shares of Novavax catapulting to $35. This would represent a 600% increase from the $5 shares closed at on Jan. 5.
Perhaps the biggest pendulum swing for Novavax is pending arbitration concerning orders for its COVID-19 vaccine with Gavi, a nongovernmental global vaccine organization. Gavi is seeking $700 million following the cancellation of a contract with Novavax for 350 million doses of its COVID-19 vaccine.
If Novavax owes nothing, its financial foundation would be greatly improved. Meanwhile, if it has to pay $700 million to Gavi, its ability to continue as a solvent company may come into question.
Cost-cutting is another big catalyst in 2024 for Novavax. The company practically halved its operating expenses through the first nine months of 2023 -- a $950 million reduction when compared to the comparable period in 2022 -- and has plans to slash another $300 million in full-year costs in the new year. If Novavax can meet these aggressive cost-cutting goals, it should meaningfully reduce its rate of cash burn.
The other wild card here is figuring out what happens with COVID-19 vaccine demand. Novavax used traditional methods to develop a protein-based vaccine, which is markedly different than the messenger-RNA vaccines developed by Moderna and Pfizer/BioNTech. If Novavax were to see stronger demand for its COVID-19 vaccine, or gather momentum as it kicks off late-stage studies for a combination vaccine (influenza and COVID-19), it's possible shares could enjoy significant upside in the new year.
While I'm not nearly as bullish on Novavax as Bernardino, a triple-digit gain could be in the cards in 2024 if things fall Novavax's way.
New, highly mutated COVID variants ‘Pirola’ BA.2.86 and JN.1 may cause more severe disease, new studies suggest
Fortune
January 8, 2024
https://fortune.com/well/2024/01/08/covid-omicron-variants-pirola-ba286-jn1-more-severe-disease-lung-gi-tract-symptoms/amp/
“We cannot ignore the evidence that Omicron may be evolving into a more severe form of itself", one researcher told Fortune.
Highly mutated COVID variant BA.2.86—close ancestor of globally dominant “Pirola” JN.1—may lead to more severe disease than other Omicron variants, according to two new studies published Monday in the journal Cell.
In one study, researchers from Ohio State University performed a variety of experiments using a BA.2.86 pseudovirus—a lab-created version that isn’t infectious. They found that BA.2.86 can fuse to human cells more efficiently and infect cells that line the lower lung—traits that may make it more similar to initial, pre-Omicron strains that were more deadly.
In the other study, researchers in Germany and France came to the same conclusion. “BA.2.86 has regained a trait characteristic of early SARS-CoV-2 lineages: robust lung cell entry,” the authors wrote. The variant “might constitute an elevated health threat as compared to previous Omicron sublineages,” they added.
While illness caused by the initial Omicron strain was typically considered more mild than that caused by earlier variants, it’s impossible to say definitively, experts say. That’s because those sickened by Omicron had generally already been infected with an earlier version of the virus, likely softening the blow. Additionally, many had been vaccinated, to the same effect.
Still, Omicron had a penchant for infecting the upper airway versus the lower airway, where prior versions of the virus tended to accumulate, causing more severe disease. The new studies offer proof that this trend may very well be reversing, the authors contend. If true, it’s bad news for those who hoped the virus was slowly attenuating to the equivalent of a common cold.
“We cannot ignore the evidence” that Omicron may be evolving into a more severe form of itself, Dr. Shan-Lu Liu—professor and co-director of the Viruses and Emerging Pathogens Program at Ohio State University, and lead author on the first study—told Fortune.
Increasing COVID hospitalizations in the U.S. and around the globe potentially bolster the argument, he added.
It’s tough to tell if disease caused by COVID is again becoming more severe because waning immunity muddles matters, experts say. Antibody immunity to COVID from vaccination or prior infection—which can reduce the severity of the disease or prevent infection altogether—declines after three to six months. Globally, uptake of the latest COVID booster, released this past fall, leaves much to be desired. In the U.S., it sits under 20%, according to the Centers for Disease Control and Prevention. In theory, the longer it’s been since someone was infected with COVID or received a booster, the greater their risk for severe outcomes like hospitalization and death.
Is JN.1 more severe than Omicron?
As for what the studies might mean regarding the severity of JN.1 infection, the jury is still out. But the new findings—combined with expert speculation that JN.1 may be showing a preference for infecting the GI tract—warrant more study into the evolving nature of the virus, according to Liu.
Another concern of his: the possibility of COVID recombining with another coronavirus in animals, then transitioning back over to humans—throwing another viral plot twist into the pandemic’s narrative.
Some experts contend that Omicron—highly mutated compared to previous strains—originated in animals, then spilled back over into humans (as opposed to developing in a human with a long-term infection, as others contend). Regardless, animals serve as an underappreciated wild card, Liu contends. Case in point: Many of Ohio’s white-tailed deer have tested positive for COVID, affording the virus an additional population in which to mutate.
Another, perhaps larger concern of Liu: the possibility that COVID recombines with another, more deadly coronavirus like SARS or MERS, which had case fatality rates around 10% and 34%, respectively. In contrast, COVID’s case fatality rate, among unvaccinated Americans, sat around 1% prior to Omicron, and around 0.11% after.
“Anything can happen,” Liu said. “It’s really hard to predict what’s going to come next, but nature can do amazing things.”
The bottom line when it comes to the power of animals to further evolve the virus and send another curveball flying humanity’s way: “Humans, watch out.”
Novavax Investor Presentation for J.P. Morgan Healthcare Conference
Filed today as part of 8-K SEC filing.
LINK: Presentation
Todos Share Update - 1/5/24
No shares issued since update on 12/8/23.
https://www.otcmarkets.com/stock/TOMDF/security
How many times did I recommend you SELL your Todos shares since you were so miserable being an investor? Many times.
How many time did I recommend you BUY Todos shares? ZERO
I hate to burst your bubble, but me buying Todos shares isn't an invitation for others to buy. In your fantasy world of laying blame on others, I guess it seems that way. Wake up!
Please tell us about all the other penny stocks you've been invested in that got traditional business loan financing from all the plethora of financial institutions willing to make those loans to a high-risk OTC company, vs. the number of financial institutions lined up to make toxic loans to high-risk OTC companies needing cash to fund operations and business goals to try to reach profitability one day. You and others posting here sound like experts, so show us some examples of how similar OTC companies comparable to Todos and Amarantus did it without toxic lending involved.
I have my reasons for investing here. I've stated many times it may not work out. I'm still holding to see what unfolds. My decision. Blaming GC is pathetically immature when you had the choice to sell and minimize your losses and chose not to sell. No one loves a crybaby who can't accept any responsibility for their decisions... except on this board with the clown posse blaming everyone but themselves.
Todos Share Update - 12/29/23
No shares issued since update on 12/8/23.
https://www.otcmarkets.com/stock/TOMDF/security
No one posting here is fleecing anyone. If someone posts they bought shares, and especially if they provided proof, and they're telling other readers that they understand the risk and are being ridiculed by the clown posse that posts here, it's not fleecing. How is that encouraging anyone else to buy shares? If you're buying shares solely because someone else here is buying, you really need to stick to mutual funds or a simple savings account with your money.
I have to answer to no one except myself. I won't be crying here for a decade if I lose my investment. Can't say that for most here that aren't current shareholders.
I took my Tollovid today.
GC hasn't posted anything on X about the news release. Sorry, just returned from a trip, and was hoping something was there.
Todos Share Update - 12/22/23
No shares issued since update on 12/8/23.
https://www.otcmarkets.com/stock/TOMDF/security
Storage requirements and shelf life are dramatically better and simpler with Novavax than for the Pfizer and Moderna mRNA vaccines. As a pharmacy, it's a lot easier to manage Novavax inventory than the mRNA options. Lots of news stories out there to back this up.
Novavax reported to be available at CVS pharmacies nationwide, but my local CVS doesn't offer Novavax and no plans to offer it. I got my Novavax vaccination at Costoco pharmacy in another nearby city. Like you and Red, simple and no side effects at all. I did, however, continue my two Tollovid per day.
And Covid has now been shown to cause microclots and damage the heart muscle in many folks who have had the virus. Have you noticed a lot more famous people dropping dead in the news over the last 2 years? Seriously, even athletes who are in great physical condition aren't immune. People are dying from heart attacks at alarmingly young ages compared to before the virus. Some believe the vaccines are responsible, and they may play a part, but as GC has stated many times on X... the virus is much worse on the body than the vaccines. Now, with that said, I WILL NOT get another mRNA vaccine. I will stick with the traditional protein-based Novavax.
Best strategy for me is combination of antiviral (Tollovid) and Novavax vaccine. Long Covid will never happen to those of us who remain free of a Covid infection. Most of my coworkers have had Covid at least once, some several times. I took Tollovid for the last few years and remain Covid-free. But hey, those who had Covid multiple times are free to form their own opinions as they visit their 9 specialists, if that makes them feel warm and fuzzy.
WB was treated with dexamethasone and it helped his symptoms but didn't treat the virus. There's plenty of documented cases where a person tests positive and later negative, where the virus has moved from the lungs and respiratory tract to other organs in the body, and the nasal or throat swabs indicate negative. Many with Long Covid show negative on these tests both with rapid and PCR methods. However, autopsies reveal massive virus still infecting organs, brain, etc. Stool samples indicate active Covid-19 viral activity still in the body. Wastewater testing in most areas indicate plenty of Covid-19 viral activity and it's increasing dramatically. It seems pretty clear WB still has Covid-19 virus in his body because dexamethasone wouldn't have eliminated it. I bet if WB took the time to test a stool sample, he'd find plenty of active virus. Too bad he's not a believer in Tollovid, which could stop viral replication in its tracks and allow his immune system to do it's job, assume that his immune system is still healthy.
I asked the AI ChatGPT 3.5 the following questions, and these responses support what I have found online about dexamethasone.
The funniest thing about all of this is that healthcare professionals ARE using Tollovid in treating Covid and Long Covid patients. The WB cannot accept that fact and will continue to post the disclaimer Todos is required to state as proof it doesn't work. It's either Gerald Derangement Syndrome or decline in mental ability as a result of active Covid-19 virus still doing damage to the brain. Either condition would explain the inability to fact that medical professionals are having success with Tollovid.
Todos Share Update - 12/15/23
No shares issued since update on 12/8/23.
https://www.otcmarkets.com/stock/TOMDF/security
Yes, tempted myself. Great offer. Best price per bottle I've ever seen.
CEO on X - 12/13/23
Tollovid target site for 3CL protease inhibition is the site nature targets. Pfizer's Paxlovid targets a different site on the protein, which Dr. Arad has previously stated is likely more susceptible to viral mutations rendering it less effective. Paxlovid is based on her earlier research, while Tollovid is based on her latest research. I know I'm using the better product and thankful that Dr. Arad and Todos has made it available to me.
If I'm a fool with his money, then I will own it and accept responsibility for my actions. Unlike many here who blame the CEO or other investors who lead them to their fate. I'm confident if the shoe was on the other foot and they made a fortune in this investment, they would point to only themselves as the savvy investor who had the foresight to invest. Take responsibility for wins, defer blame for losses. That seems to be the way of the world nowadays. Where do you fall in that spectrum?
I've posted when I purchased shares. Some thought I was lying so I posted proof of my buys. I haven't sold any shares. It's called accumulating based on what I believe may unfold with Todos. I might be wrong, so feel free to ignore what I'm doing. Everyone has to decide for themselves, but anyone blaming me for leading them down this path shouldn't be investing if they can't make their own decisions and accept responsibility. My suggestion to those people is to "F*ck Off".
I bought a ton in my Roth because I was putting $50K or more per year in the Roth, and directed a lot of that towards Todos shares. I also bought a lot in my regular IRA and in a fully taxable account. My Todos holdings are split across all three accounts. My suggestion for using a Roth was under the assumption someone was already going to buy Todos shares, so buying in a Roth would eliminate tax on gains and withdrawals... a very nice place to be if the company succeeded. The drawback is you can't uses losses against ordinary income to save on taxes. You can't do that with a regular IRA either.
So what's your point?
I'm not posting to try to get someone to invest so I can unload my shares. I'm seeing this story through to the conclusion. I may or may not choose to buy more shares, depending on my outlook. My risk tolerance is likely different from yours.
If you believe Red and I and a few others are pumping this stock, you're wrong. Head over the the MONI board and you'll see a true pump and dump in action. You're not seeing any of us suggesting where the Todos share price will be at some point. Yes, we are invested because we believe it will be higher. I only have to get to 0.4 cents to break even. I certainly believe this can go higher than that if things continue with the way Long Covid is going. Anyone still invested here who doesn't believe it will go higher should simply exit and move on. There's a positive psychological aspect to closing out of a losing investment and moving on. Learn from the experience and become better with the next investment decision.
Those who suggest several of us here are back office boys working for Todos are delusional and complete morons. You know who I'm speaking of. Look at how they pump on MONI and IBIO boards. I seriously wish some would just put those of us invested here on ignore, but that's not their agenda.
Here's another thought to consider... the company is clearly issuing shares to fund operations. Who is buying those shares? Who would buy shares in this company on that level if they believe the company and their products are toast? That's a topic no one seems to want to address.
I'm not enticing anyone to buy. My money, my outlook, my decision to invest. If you have a different opinion, then don't invest. The board is for discussion of Todos, products, and where we believe things may go. But when you make the claim EVERYONE is down 99.9%, that opens you up to correction.
Everyone is not down 99.9%. Some continued to pick up larger and larger numbers of shares as the price declined, and continue to buy even now. That can have a pretty dramatic impact on cost basis.
Try again. Make another assumption.
Why do you continue to respond to this AssClown? Block him like Red and I have done. Your life will improve dramatically when you remove his insane rants from your life. You also won't have to deal with his vulgar private messages if he's blocked.
And certainly don't invest in any company he invests in, unless you enjoy losing money. One of the most consistently wrong investors I've ever witnessed based on his posting history. Insanely skilled at picking losers.
There is an Israeli product called Enovid that's a nasal spray I purchased last year. It's designed to be carried with you and used when you're around other people, before or after contact. It kills the virus in the nasal passages and can be used to help prevent infection. It uses a patented injector that creates nitrous oxide immediate with each injection, which kills the virus.
I can provide the info if you're interested. When I purchased 3 bottles it was $40/bottle, and each bottle lasts about 2 months with daily use. I used it occasionally while at work, but another family member swears by it and says it cleared up his sinus issues better than anything he's tried before, while also providing protection against Covid infection. I suspect the nitrous oxide cleared up other long-standing infections that had become resistant over time to the drugs he was being prescribed.